Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | JAK3 | P52333 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20915035 | 0.84 | — | — | |
| SCHEMBL23009924 | 0.81 | TDP1 (0.48) | TSHRKDM4EKMT2AALDH1A1HSD17B10 | |
| SCHEMBL23009977 | 0.78 | TSHR (0.41) | TSHRKDM4EKMT2AALDH1A1HSD17B10 | |
| SCHEMBL20029633 | 0.76 | KDM4E (0.39) | TSHRKDM4EKMT2AALDH1A1HSD17B10 | |
| SCHEMBL3261638 | 0.76 | TSHR (0.52) | TSHRKDM4EKMT2AALDH1A1HSD17B10 | |
| SCHEMBL29192762 | 0.75 | KMT2A (0.36) | TSHRKDM4EKMT2AALDH1A1MEN1 | |
| SCHEMBL23009920 | 0.75 | TSHR (0.38) | TSHRKDM4EKMT2AALDH1A1HSD17B10 | |
| SCHEMBL21804494 | 0.75 | TSHR (0.49) | TSHRKDM4EKMT2AALDH1A1HSD17B10 | |
| SCHEMBL17786779 | 0.75 | TSHR (0.49) | TSHRKDM4EKMT2AALDH1A1HSD17B10 | |
| SCHEMBL21805554 | 0.74 | TSHR (0.47) | TSHRKDM4EKMT2AALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3697774-B1 | CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS | VERTEX PHARMA (US) | 2025-09-24 | — | — | EP | disclosed |
| CN-111757874-B | Methods for preparing modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-109803962-B | Modulators of cystic fibrosis transmembrane conductance regulator proteins, and pharmaceutical compositions | 弗特克斯药品有限公司 | 2022-04-29 | — | — | CN | disclosed |
| US-11155533-B2 | Crystalline forms and compositions of CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-10-26 | — | — | US | disclosed |
| US-20200392109-A1 | CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-12-17 | — | — | US | disclosed |
| CN-111757874-A | Method for producing modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2020-10-09 | — | — | CN | disclosed |
| EP-3697774-A1 | CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS | Vertex Pharmaceuticals Incorporated (US) | 2020-08-26 | — | — | EP | disclosed |
| US-10654829-B2 | Crystalline forms and compositions of CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-05-19 | — | — | US | disclosed |
| WO-2019079760-A1 | CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-04-25 | — | — | WO | disclosed |
| US-20190119253-A1 | CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS | VERTEX PHARAMCEUTICALS INCORPORATED (US) | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11155533-B2 | Crystalline forms and compositions of CFTR modulators | CFTR, SLC26A4, ABCC4 | TSHR 3141/4885KDM4E 4781/4885KMT2A 4795/4885 |
| US-20190119253-A1 | CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS | CFTR, SLC26A4, ABCC4 | TSHR 3212/4885KDM4E 4599/4885KMT2A 4657/4885 |
| US-20200392109-A1 | CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS | CFTR, SLC26A4, ABCC4 | TSHR 3141/4885KDM4E 4781/4885KMT2A 4795/4885 |
| US-10654829-B2 | Crystalline forms and compositions of CFTR modulators | CFTR, SLC26A4, ABCC4 | TSHR 3141/4885KDM4E 4781/4885KMT2A 4795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.